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ABSTRACT
Objective: To study the risk factors, clinical characteristics, and outcome in patients with infections due to CRE infections.
Methods: Retrospective study was carried out in a microbiology laboratory for 6 months. 152 CRE isolates identified by the Vitek 2 compact system 
were included in the study. The risk factors, antibiotic treatment and clinical outcome were studied from the case sheets, Chi-square test was used for 
statistical analysis.
Results: Of the 2520 positive cultures for Enterobacteriaceae, isolation rate of CRE was 152 (6%). 76 (50%) belonged to exudates, 22 (14.1%) blood 
culture, 90 (59.2%) urine. The common infection was UTI. The risk factors were prior exposure to antimicrobials, admission to intensive care unit, 
indwelling devices and prior hospitalization. The effective antibiotic was colistin, polymyxin B, tigecycline, cefoperazone-sulbactum, piperacillin-
tazobactum. The mortality was 19.7%.
Conclusion: We have demonstrated the value of understanding local epidemiology to help modify our risk-based screening as a strategy to limit the 
spread of CRE.
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INTRODUCTION
The infections caused by Enterobacteriaceae family include urinary 
tract infections (UTIs), bloodstream infections, hospital-acquired 
pneumonias and various intra-abdominal infections.
The Enterobacteriaceae are among the most common etiologic agents 
that cause healthcare-associated infections.
The rise in the number of extended-spectrum beta-lactamases 
producing Enterobacteriaceae made carbapenems the drug of choice 
in the treatment of multidrug-resistant (MDR) Enterobacteriaceae. 
Because of their safety and established efficacy, the carbapenems used 
to serve as the ultimate last resort option for treating MDR [1].
The family of bacteria known as the carbapenem-resistant 
Enterobacteriaceae is an emerging group of Gram-negative bacilli 
that have become resistant to all or nearly all antibiotics and are 
causing infections with significant morbidity and mortality. The 
rates of carbapenem resistance have increased over the past decade. 
The prevalence of carbapenem-resistant Enterobacteriaceae (CRE), 
according to some institutions in epidemic area, varies between 24.7% 
and 29.8% [2,3].
The risk factors associated with CRE include medical devices such as 
intravenous catheters, ventilators, urinary catheters, and through 
wounds caused by injury or surgery. Because these bacteria have 
become resistant to antibiotics, CRE infections are very difficult to treat.
The emergence of CRE is a menace to patients, particularly to those who 
are debilitated, with various underlying diseases, complex infections or 
medical interventions. Moreover, pathogens resistance to carbapenems 
often shows high resistance to other antibiotic agents as well, such as 
cephalosporins, quinolones and aminoglycosides, leaving few or, in 
some cases, no optimal therapeutic options. What’s more, some extra 
factors, such as delayed identification, lack of accurate judgment of 
pathogens, also lead to high mortality, prolonged hospital stay, and 
huge medical expenses in CRE-infected patients [4,5].
The study undertaken aims to look into the common Gram-negative 
bacterial infections mainly of the Enterobacteriaceae family which 
are resistant to the carbapenems and the etiological agents of these 
infections. The antibiotic audit in these cases and the risk factor analysis 
will help us to look into the areas of interventions which can be taken 
up to prevent the emergence and spread of the CRE.
In this study, we aim to study the risk factors, clinical characteristics, 
and outcome in patients with infections due to CRE infections.
Objectives
1. To identify the common infections caused by CRE.
2. To identify the risk factors associated with CRE infections.






Microbiology laboratory of a tertiary care center.
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Study duration
6 months (June 2016 to November 2016).
Sample size
The total number of samples received during the 6 months period.
Inclusion criteria
•	 Enterobacteriacae	 isolates	 from	 clinically	 significant	 samples	
over a period of 6 months will be included in the study. Blood 
and	cerebrospinal	fluid	sample	having	any	growth	are	considered	
clinically	 significant.	 Pus	 samples	 and	 lower	 respiratory	 tract	
aspirates associated with numerous polymorphonuclear cells are 
considered	clinically	significant,	and	urine	sample	showing	growth	of	
more than 105 organisms or more than 103 organisms in symptomatic 
patients	is	considered	clinically	significant.
•	 Only	 the	 isolates	 of	Enterobacteriaceae which are resistant to 
carbapenem group of antibiotics will be included in the study.
Exclusion criteria





The CRE isolates from various samples such as pus, urine, blood 
identified by conventional methods/automated Vitek 2 compact system 
and the antibiotic susceptibility of the isolates was done by modified 
Kirby-Bauer disk diffusion method according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines on Muller-Hinton agar plates. The 
results were interpreted using CLSI guidelines. The antibiogram was 
noted.
Data collection
The clinical details were collected using a pro forma from the case sheets 
of the patients. Detailed clinical history is to be obtained which will 
include information such as age, sex, duration of hospital stay, history 
of chronic disease, history of instrumentation, or device implantation.
The demographics, risk factors, clinical characteristics, antibiotic 
exposure, and outcome shall be noted. The empirical antibiotic given, 
any changes/de-escalation done after receiving the report, duration 
of antibiotic treatment will be noted from the case sheets. The 
information will be obtained from the medical records department of 
the hospitals.
Ethical committee clearance
The present study has been approved by the Institutional Ethics 
Committee.
Data analysis
Chi-square test and odds ratio were used to find out association 
between the different risk factors for CRE was also estimated. The 
statistical package SPSS version 17.0 was used to perform the analyses.
RESULTS
Of the 2520 positive cultures for Enterobacteriaceae, isolation rate of 
CRE was 152 (6%). Among 152 CRE isolates, 76 (50%) belonged to 
exudates, 22 (14.1%) blood culture, and 90 (59.2%) urine. The most 
common infection was UTI. The findings of the study are shown in 
Tables 1-6.
Treatment and outcome
The empirical treatment was started with 3rd generation cephalosporins 
including ceftriaxone and cefotaxime, carabapenems (meropenem/
imipenem), amoxyclav, amikacin, vancomycin, and piperacillin-
tazobactam. The antibiotic was changed after the antibiotic sensitivity 
report based on the sensitivity pattern of each organism. The 
effective antibiotics against the CRE isolates were colistin, polymyxin 
B, tigecycline, cefoperazone-sulbactum, piperacillin-tazobactum. 
Norfloxacin/nitrofurantoin was found to be effective in UTIs.
Of the 152 CRE-infected patients, the mortality rate was 30 (19.7%). 
The immediate cause of death in these patients was sepsis with septic 
shock and multiple organ dysfunction syndrome and the underlying 
causes were malignancy, cellulitis, and chronic liver disease with portal 
hypertension.
DISCUSSION
CRE are an emerging threat and are associated with high mortality. 
CRE, selected by the use of antibiotics have become very important 
healthcare-associated pathogens. The risk factors are advanced age, 
comorbidities, and medical interventions.
The previous studies have reported that pneumonia was the most 
frequently detected infection (62.07%), followed by UTIs and central 
venous catheter-associated bloodstream infections. Prior antimicrobial 
therapy, urinary catheterization, and length of intensive care unit (ICU) 
stay were found to be risk factors. Gram-negative Enterobacteriaceae 
were the most frequently isolated pathogens, while Pseudomonas 
aeruginosa was the single most frequent causative organism in ICU 
infections [6].
The prevalence of CRE in our study population was 6% (152 of 
2520 patients), which is almost similar to the prevalence of CRE 5.4% 
(306 of 5676 patients) in previous studies done by Swaminathan et al 
in 2013 [7].
There was a varied range of infections caused by CRE in our hospital 
set up, such as UTI, sepsis, cellulitis, necrotising fasciitis, pneumonia, 
and spontaneous bacterial peritonitis which was consistent with the 
findings of previous studies conducted by Nordmann et al. in 2011 [5]. 
Interestingly, pneumonia and UTIs were the most common infections in 
previous research reported by Falagas et al. in the year 2013 [8].
Our study identified similar risk factors that other investigators have 
highlighted in their studies done in 2014 and 2015 prior exposure to 
antimicrobials such as 3rd generation cephalosporins, carbapenems and 
beta-lactam/beta-lactamase inhibitor combinations, admission to ICU, 
presence to indwelling devices for example urinary catheter, central 
line, endotracheal tube, and prior hospitalization [9,10]. This highlights 
the importance of safe patient care practices, especially in the care 
of devices as well as the significance of an antimicrobial stewardship 
program in the strategy for the prevention of CRE infections.
Infections with CRE result in poor outcomes, and available treatments 
of the past resort such as tigecycline and colistin are of unclear efficacy 
and safety [11].
Table 1: Age‑wise distribution of CRE isolates
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CRE have emerged as a potential threat in hospitals with resistance to 
many other classes of antibiotics, thus limiting our therapeutic options. 
This situation demands proper diagnosis, treatment, and control 
of infections in hospitalized patients [12]. Global increase in CRE in 
many healthcare facilities poses challenges to infection control and 
infectious disease professionals. Risk-based screening is one useful 
strategy that has been used to limit the spread. We have demonstrated 
the value of understanding local epidemiology to help modify our risk-
based screening as a strategy to limit the spread of CRE. The studies 
on transmission, mechanism of resistance, and treatment regimens are 
needed to control the spread of CRE.
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